GlassScriptPhysician profile
Tracy D Brady
NPI 1528210838
$1,056.39
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.91 · 2022: $376 · 2023: $419 · 2024: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $242.29 | 2019-2024 | Otezla, Repatha, Prolia |
| Idorsia Pharmaceuticals US INC | $138.74 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $113.64 | 2022-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $87.81 | 2022-2024 | Ozempic, Rybelsus |
| Medtronic, INC. | $70.61 | 2022-2024 | Minimed 780g, Venaseal |
| Lilly USA, LLC | $68.57 | 2022-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.20 | 2019-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $62.00 | 2022-2023 | Trelegy Ellipta |
| Abbott Laboratories | $44.26 | 2022-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $38.27 | 2019-2023 | |
| Abbvie INC. | $32.87 | 2022 | |
| Dexcom, INC. | $24.53 | 2022 | |
| Beta Bionics, INC. | $21.13 | 2024 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $17.75 | 2022 | |
| Pfizer INC. | $17.53 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.